Melflufen is protected by more than 50 granted patents and pending patent applications covering the composition of matter, formulations, manufacturing processes, and medical applications.

Stockholm – February 25, 2025 – Oncopeptides AB (publ), a biotech company focused on difficult-to-treat cancers, today announces that a new real-world study on melflufen (melphalan flufenamide, ...

Oncopeptides is developing melflufen, a first-in-class peptide-conjugated alkylator for the treatment of relapsed and refractory multiple myeloma. Oncopeptides, a pharmaceutical company based in ...